← SynDRA
MOMELOTINIB
SynDRA canonical compound SYN0021364 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | JAK1 | JAK2 | JAK3 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
All known targets
- JAK1
- JAK2
- ACVR1
- JAK3
- TYK2
Mechanisms of action (all sources)
- JAK1 INHIBITOR
- Tyrosine-protein kinase JAK1 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- ACVR1 INHIBITOR
- Activin receptor type-1 inhibitor
- JAK3 INHIBITOR
- TYK2 INHIBITOR
- JAK inhibitor
- JAK2 MODULATOR
- JAK1 MODULATOR
Drug classes
- Antineoplastic Agents
- Janus Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- CYT-387
- CYT-0387
- CYT-11387
- CYT387
- GS-0387
- Cyt387
- CYT 387
- N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide
- CYT 11387
- UNII-6O01GMS00P
- N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
- 6O01GMS00P
- CHEMBL1078178
- AK102858
- N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
- N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide
- CYT387 sulfate salt
- N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
- momelotinibum
- CHEBI:91407
- RefChem:819199
- DTXCID30200399
- Momelotinib (CYT387)
- MFCD16038899
- Ojjaara
- Momelotinib [USAN]
- C23H22N6O2
- Momelotinib [USAN:INN]
- Omjjara
- MOMELOTINIB [INN]
- Momelotinib (USAN/INN)
- MOMELOTINIB [WHO-DD]
- MLS006011154
- GTPL7791
- orb1307329
- SCHEMBL2237234
- SCHEMBL29352115
- EX-A260
Look up MOMELOTINIB in the interactive SynDRA portal →